Patents by Inventor Yumi IYOKU

Yumi IYOKU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION FOR REGENERATION OF INTERVERTEBRAL DISC
    Publication number: 20240100099
    Abstract: Provided is a composition for promotion of the regeneration of the nucleus pulposus of an intervertebral disc, said composition comprising a low endotoxin monovalent metal salt of alginic acid and mesenchymal stem cells. In particular, the composition of the present invention promotes the regeneration of the nucleus pulposus of an intervertebral disc via activation of nucleus pulposus cells by human bone marrow-derived high-purity mesenchymal stem cells and/or differentiation of human bone marrow-derived high-purity mesenchymal stem cells into nucleus pulposus cells.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 28, 2024
    Applicants: National University Corporation Hokkaido University, PuREC Co., Ltd., Mochida Pharmaceutical Co., Ltd.
    Inventors: Hideki SUDO, Daisuke UKEBA, Katsuhisa YAMADA, Katsuro URA, Hisataka SUZUKI, Yumi IYOKU, Takashi SUYAMA
  • Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method
    Patent number: 11441123
    Abstract: The present invention aims to obtain a method for quality evaluation of human mesenchymal stem cells, a method for isolation, selection and culture of human mesenchymal stem cells, a cell population of rapidly proliferating human mesenchymal stem cells, as well as monoclonal antibodies that specifically recognize rapidly proliferating human mesenchymal stem cells. From a cell population containing human mesenchymal stem cells, rapidly proliferating human mesenchymal stem cells are isolated, selected and cultured. The abundance ratio of cells expressing Ror2 or Fzd5 in the cell population thus isolated, selected and cultured is quantified to determine whether or not each cell population is acceptable.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: September 13, 2022
    Assignee: PUREC CO., LTD.
    Inventors: Yumi Iyoku, Hideyuki Okano, Yo Mabuchi
  • METHOD FOR EVALUATING QUALITY OF HUMAN MESENCHYMAL STEM CELL, AND MONOCLONAL ANTIBODY FOR USE IN SAID METHOD
    Publication number: 20210230553
    Abstract: The present invention aims to obtain a method for quality evaluation of human mesenchymal stem cells, a method for isolation, selection and culture of human mesenchymal stem cells, a cell population of rapidly proliferating human mesenchymal stem cells, as well as monoclonal antibodies that specifically recognize rapidly proliferating human mesenchymal stem cells. From a cell population containing human mesenchymal stem cells, rapidly proliferating human mesenchymal stem cells are isolated, selected and cultured. The abundance ratio of cells expressing Ror2 or Fzd5 in the cell population thus isolated, selected and cultured is quantified to determine whether or not each cell population is acceptable.
    Type: Application
    Filed: March 2, 2021
    Publication date: July 29, 2021
    Applicant: PUREC CO., LTD.
    Inventors: Yumi IYOKU, Hideyuki OKANO, Yo MABUCHI
  • METHOD FOR EVALUATING QUALITY OF HUMAN MESENCHYMAL STEM CELL, AND MONOCLONAL ANTIBODY FOR USE IN SAID METHOD
    Publication number: 20170204374
    Abstract: The present invention aims to obtain a method for quality evaluation of human mesenchymal stem cells, a method for isolation, selection and culture of human mesenchymal stem cells, a cell population of rapidly proliferating human mesenchymal stem cells, as well as monoclonal antibodies that specifically recognize rapidly proliferating human mesenchymal stem cells. From a cell population containing human mesenchymal stem cells, rapidly proliferating human mesenchymal stem cells are isolated, selected and cultured. The abundance ratio of cells expressing Ror2 or Fzd5 in the cell population thus isolated, selected and cultured is quantified to determine whether or not each cell population is acceptable.
    Type: Application
    Filed: July 31, 2015
    Publication date: July 20, 2017
    Applicant: PUREC CO., LTD.
    Inventors: Yumi IYOKU, Hideyuki OKANO, Yo MABUCHI